Linical Co., Ltd.

TSE:2183 Voorraadrapport

Marktkapitalisatie: JP¥8.2b

Linical Inkomsten in het verleden

Verleden criteriumcontroles 2/6

Linical has been growing earnings at an average annual rate of 9.2%, while the Life Sciences industry saw earnings growing at 25.6% annually. Revenues have been growing at an average rate of 3.7% per year. Linical's return on equity is 3.1%, and it has net margins of 2.1%.

Belangrijke informatie

9.2%

Groei van de winst

9.2%

Groei van de winst per aandeel

Life Sciences Groei van de industrie32.0%
Inkomstengroei3.7%
Rendement op eigen vermogen3.1%
Nettomarge2.1%
Volgende winstupdate14 Nov 2024

Recente prestatie-updates uit het verleden

There May Be Some Bright Spots In Linical's (TSE:2183) Earnings

May 22
There May Be Some Bright Spots In Linical's (TSE:2183) Earnings

Recent updates

There May Be Some Bright Spots In Linical's (TSE:2183) Earnings

May 22
There May Be Some Bright Spots In Linical's (TSE:2183) Earnings

Some Linical Co., Ltd. (TSE:2183) Shareholders Look For Exit As Shares Take 26% Pounding

Mar 08
Some Linical Co., Ltd. (TSE:2183) Shareholders Look For Exit As Shares Take 26% Pounding

Linical (TSE:2183) Is Paying Out A Larger Dividend Than Last Year

Feb 26
Linical (TSE:2183) Is Paying Out A Larger Dividend Than Last Year

Opbrengsten en kosten

Hoe Linical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

TSE:2183 Opbrengsten, kosten en inkomsten (JPY Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 2412,1512532,6600
31 Mar 2412,3073382,7050
31 Dec 2312,5186802,5900
30 Sep 2312,6607142,6050
30 Jun 2312,7309312,5880
31 Mar 2312,5161,0042,5090
31 Dec 2212,1888432,5930
30 Sep 2211,9531,0062,4840
30 Jun 2211,6397992,3760
31 Mar 2211,5557902,1860
31 Dec 2111,3609062,0860
30 Sep 2110,8208042,0100
30 Jun 2110,6398051,9590
31 Mar 2110,2795392,0160
31 Dec 2010,2622412,0590
30 Sep 2010,5272392,0800
30 Jun 2010,6792682,1800
31 Mar 2010,9354822,1690
31 Dec 1910,9445082,0650
30 Sep 1911,0904092,0570
30 Jun 1911,2345412,0320
31 Mar 1911,3135682,1890
31 Dec 1810,9758532,2540
30 Sep 1810,4061,1472,0570
30 Jun 189,7361,1771,8420
31 Mar 189,1131,2951,5110
31 Dec 178,8701,2811,5080
30 Sep 178,6451,2371,4900
30 Jun 178,5411,3811,4440
31 Mar 178,3551,4471,3890
31 Dec 168,1311,3751,4410
30 Sep 167,9161,3311,4250
30 Jun 167,8911,3681,3820
31 Mar 167,6661,3301,3420
31 Dec 157,4201,1541,3100
30 Sep 156,6441,0151,1320
30 Jun 155,5495799910
31 Mar 154,8724378620
31 Dec 144,2314657750
30 Sep 144,0224297550
30 Jun 143,9094457460
31 Mar 143,7214497140
31 Dec 133,6924737230

Kwaliteitswinsten: 2183 has high quality earnings.

Groeiende winstmarge: 2183's current net profit margins (2.1%) are lower than last year (7.3%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 2183's earnings have grown by 9.2% per year over the past 5 years.

Versnelling van de groei: 2183's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Winst versus industrie: 2183 had negative earnings growth (-72.8%) over the past year, making it difficult to compare to the Life Sciences industry average (-32.8%).

Rendement op eigen vermogen

Hoge ROE: 2183's Return on Equity (3.1%) is considered low.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y